

Table 8. Study results

	L-AmB	CAB
% still receiving initial dose during the final three days of therapy	51%	56%
% receiving reduced dose	15%	27%
% receiving increased dose	33%	18%
Success rate	50.1%	49.4%
Incidence of invasive breakthrough fungal infections	3.2%	7.8%
No. of patients who died	25	36
Infusion-related reactions (3,622 infusions for L-AmB and 3,403 infusions for CAB)		
Day 1 — Fever	267 (7.4%)	544 (16.0%)
Other infusion-related reactions except fever	746 (20.6%)	1,776 (52.2%)
Nephrotoxicity (doubling of SCr or SCr > 3.0)	12%	26%
Mean change from baseline	0.48 mg/dL	0.77 mg/dL